Therapeutic development to accelerate malaria control through intentional intervention layering
Abstract The clinical development of novel vaccines, injectable therapeutics, and oral chemoprevention drugs has the potential to deliver significant advancements in the prevention of Plasmodium falciparum malaria. These innovations could support regions in accelerating malaria control, transforming...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Malaria Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12936-024-05222-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594957235388416 |
|---|---|
| author | Lydia Braunack-Mayer Narimane Nekkab Josephine Malinga Sherrie L. Kelly Evelyn Ansah Joerg J. Moehrle Melissa A. Penny |
| author_facet | Lydia Braunack-Mayer Narimane Nekkab Josephine Malinga Sherrie L. Kelly Evelyn Ansah Joerg J. Moehrle Melissa A. Penny |
| author_sort | Lydia Braunack-Mayer |
| collection | DOAJ |
| description | Abstract The clinical development of novel vaccines, injectable therapeutics, and oral chemoprevention drugs has the potential to deliver significant advancements in the prevention of Plasmodium falciparum malaria. These innovations could support regions in accelerating malaria control, transforming existing intervention packages by supplementing interventions with imperfect effectiveness or offering an entirely new tool. However, to layer new medical tools as part of an existing programme, malaria researchers must come to an agreement on the gaps that currently limit the effectiveness of medical interventions for moderate to low transmission settings. In this perspective, three crucial gaps that may prevent new therapeutics from being used to their fullest extent are presented. First, do burden reduction outcomes, which are typically monitored in studies of new medical products, sufficiently capture the broader goal of accelerating malaria control? Layering novel malaria products requires monitoring health outcomes that reflect the novel product’s targeted stage of the parasite life cycle, in addition to all-infection and prevalence-based outcomes. Second, what public health outcome does a novel medical prevention tool provide that existing malaria interventions cannot fully deliver? Novel medical tools should be developed not just for an incremental improvement in preventive efficacy over an existing product, but also to meet a gap in protection. Specifically, this means designing products with components that target parts of the parasite life cycle beyond the scope of existing therapeutics, and better addressing populations and settings not well covered by existing tools. Finally, when do the population-level benefits of a multi-tool prevention programme justify the individual-level outcomes from receiving multiple interventions? An individual-level perspective should be key for exploring when and how layering a novel prevention intervention can accelerate efforts towards P. falciparum malaria control. |
| format | Article |
| id | doaj-art-2297262a07ca4a35bdd3e49e39ce95cf |
| institution | Kabale University |
| issn | 1475-2875 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Malaria Journal |
| spelling | doaj-art-2297262a07ca4a35bdd3e49e39ce95cf2025-01-19T12:11:10ZengBMCMalaria Journal1475-28752025-01-012411910.1186/s12936-024-05222-4Therapeutic development to accelerate malaria control through intentional intervention layeringLydia Braunack-Mayer0Narimane Nekkab1Josephine Malinga2Sherrie L. Kelly3Evelyn Ansah4Joerg J. Moehrle5Melissa A. Penny6Swiss Tropical and Public Health InstituteSwiss Tropical and Public Health InstituteThe Kids Research Institute AustraliaSwiss Tropical and Public Health InstituteUniversity of Health and Allied SciencesSwiss Tropical and Public Health InstituteSwiss Tropical and Public Health InstituteAbstract The clinical development of novel vaccines, injectable therapeutics, and oral chemoprevention drugs has the potential to deliver significant advancements in the prevention of Plasmodium falciparum malaria. These innovations could support regions in accelerating malaria control, transforming existing intervention packages by supplementing interventions with imperfect effectiveness or offering an entirely new tool. However, to layer new medical tools as part of an existing programme, malaria researchers must come to an agreement on the gaps that currently limit the effectiveness of medical interventions for moderate to low transmission settings. In this perspective, three crucial gaps that may prevent new therapeutics from being used to their fullest extent are presented. First, do burden reduction outcomes, which are typically monitored in studies of new medical products, sufficiently capture the broader goal of accelerating malaria control? Layering novel malaria products requires monitoring health outcomes that reflect the novel product’s targeted stage of the parasite life cycle, in addition to all-infection and prevalence-based outcomes. Second, what public health outcome does a novel medical prevention tool provide that existing malaria interventions cannot fully deliver? Novel medical tools should be developed not just for an incremental improvement in preventive efficacy over an existing product, but also to meet a gap in protection. Specifically, this means designing products with components that target parts of the parasite life cycle beyond the scope of existing therapeutics, and better addressing populations and settings not well covered by existing tools. Finally, when do the population-level benefits of a multi-tool prevention programme justify the individual-level outcomes from receiving multiple interventions? An individual-level perspective should be key for exploring when and how layering a novel prevention intervention can accelerate efforts towards P. falciparum malaria control.https://doi.org/10.1186/s12936-024-05222-4Plasmodium falciparumMalariaIntervention layeringIntervention mixingModelling |
| spellingShingle | Lydia Braunack-Mayer Narimane Nekkab Josephine Malinga Sherrie L. Kelly Evelyn Ansah Joerg J. Moehrle Melissa A. Penny Therapeutic development to accelerate malaria control through intentional intervention layering Malaria Journal Plasmodium falciparum Malaria Intervention layering Intervention mixing Modelling |
| title | Therapeutic development to accelerate malaria control through intentional intervention layering |
| title_full | Therapeutic development to accelerate malaria control through intentional intervention layering |
| title_fullStr | Therapeutic development to accelerate malaria control through intentional intervention layering |
| title_full_unstemmed | Therapeutic development to accelerate malaria control through intentional intervention layering |
| title_short | Therapeutic development to accelerate malaria control through intentional intervention layering |
| title_sort | therapeutic development to accelerate malaria control through intentional intervention layering |
| topic | Plasmodium falciparum Malaria Intervention layering Intervention mixing Modelling |
| url | https://doi.org/10.1186/s12936-024-05222-4 |
| work_keys_str_mv | AT lydiabraunackmayer therapeuticdevelopmenttoacceleratemalariacontrolthroughintentionalinterventionlayering AT narimanenekkab therapeuticdevelopmenttoacceleratemalariacontrolthroughintentionalinterventionlayering AT josephinemalinga therapeuticdevelopmenttoacceleratemalariacontrolthroughintentionalinterventionlayering AT sherrielkelly therapeuticdevelopmenttoacceleratemalariacontrolthroughintentionalinterventionlayering AT evelynansah therapeuticdevelopmenttoacceleratemalariacontrolthroughintentionalinterventionlayering AT joergjmoehrle therapeuticdevelopmenttoacceleratemalariacontrolthroughintentionalinterventionlayering AT melissaapenny therapeuticdevelopmenttoacceleratemalariacontrolthroughintentionalinterventionlayering |